NEW FRONTIER IN CANCER IMMUNOTHERAPY: NEXT-GENERATION CAR-T CELLS, CRISPR-CAS9 GENOME EDITING, TUMOR RESISTANCE, AND THE CHALLENGES OF EXPANDING CELLULAR THERAPIES TO SOLID AND HEMATOLOGICAL NEOPLASMS

Authors

  • Isabelle Giovanna Teixeira de Mendonça
  • Cristiane de Souza
  • Bárbara Amaral da Silva
  • Luiza Satie Trad Ichiy
  • Daniele Rodrigues Fidelis
  • Maria Eduarda Maschion Pinto
  • Angélica Caroline de Freitas Silva
  • Rivonilda Machado dos Santos de Santana Graim
  • Jair Francisco de Santana Graim
  • Beto Cherles Coral Rodrigues
  • Ricardo Rodrigues Lucas

DOI:

https://doi.org/10.63330/sasciencesv6n2-310

Keywords:

CAR-T cells, Cellular immunotherapy, CRISPR-Cas9, Neoplasms, Tumor resistance

Abstract

Cancer immunotherapy based on chimeric antigen receptor T cells (CAR-T cells) represents a major advance in the treatment of certain hematological malignancies and has attracted growing interest because of its potential application in solid tumors. This study aims to analyze advances in next-generation CAR-T cells, applications of CRISPR-Cas9 genome editing, and the main mechanisms of tumor resistance that limit the effectiveness of these therapies. It consists of a qualitative and descriptive literature review based on scientific publications addressing cellular immunotherapy, genetic engineering, and translational oncology. The literature indicates that CAR-T cell therapies have achieved relevant clinical outcomes in certain hematological malignancies, whereas their application in solid tumors remains limited by antigenic heterogeneity, the immunosuppressive tumor microenvironment, and difficulties involving cellular infiltration and persistence. CRISPR-Cas9 genome editing offers potential to improve the functionality of engineered cells and expand opportunities for developing allogeneic cellular products, although challenges related to safety, efficacy, and manufacturing remain. The study concludes that expanding these therapies depends on overcoming resistance mechanisms, improving cellular engineering strategies, and increasing access to treatment.

Downloads

Download data is not yet available.

References

GIL, Antônio Carlos. Como elaborar projetos de pesquisa. 4. ed. São Paulo: Atlas, 2002.

MAUDE, Shannon L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. The New England Journal of Medicine, v. 378, n. 5, p. 439-448, 2018. DOI: 10.1056/NEJMoa1709866.

MINAYO, Maria Cecília de Souza. O desafio do conhecimento: pesquisa qualitativa em saúde. 14. ed. São Paulo: Hucitec, 2014.

SNYDER, Hannah. Literature review as a research methodology: an overview and guidelines. Journal of Business Research, v. 104, p. 333-339, 2019. DOI: 10.1016/j.jbusres.2019.07.039.

STADTMAUER, Edward A. et al. CRISPR-engineered T cells in patients with refractory cancer. Science, v. 367, n. 6481, eaba7365, 2020. DOI: 10.1126/science.aba7365.

STERNER, Robert C.; STERNER, Rosalie M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer Journal, v. 11, art. 69, 2021. DOI: 10.1038/s41408-021-00459-7.

Downloads

Published

2026-11-11

How to Cite

de Mendonça, I. G. T. ., de Souza, C. ., da Silva, . B. A. ., Ichiy, L. S. T. ., Fidelis, D. R. ., Pinto, M. E. M. ., Silva, A. C. de F. ., Graim, R. M. dos S. de S. ., Graim, J. F. de S. ., Rodrigues, B. C. C. ., & Lucas, R. R. . (2026). NEW FRONTIER IN CANCER IMMUNOTHERAPY: NEXT-GENERATION CAR-T CELLS, CRISPR-CAS9 GENOME EDITING, TUMOR RESISTANCE, AND THE CHALLENGES OF EXPANDING CELLULAR THERAPIES TO SOLID AND HEMATOLOGICAL NEOPLASMS. South American Sciences, 6(2), e26539. https://doi.org/10.63330/sasciencesv6n2-310

Issue

Vol. 6 No. 2 (2026): South American Sciences

Section

Artigos

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Autores concordam com os seguintes termos:

a) Os autores mantêm os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a LicençaAttribution-NonCommercial-ShareAlike 4.0 International, que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial na Revista SAS. A licença permite o uso, a distribuição e a reprodução irrestrita, em qualquer meio, desde que devidamente citada a fonte. Essa licença permite também que outros remixem, adaptem e criem a partir do seu trabalho para fins não comerciais, desde que atribuam a você o devido crédito e que licenciem as novas criações sob termos idênticos.

b) Não cabe aos autores compensação financeira a qualquer título, por artigos ou resenhas publicados na South American Sciences.

c) Os conceitos expressos nos artigos publicados na South American Sciences são de inteira responsabilidade de seus autores.

Most read articles by the same author(s)